两例TENIS综合征患者99mTc-FAPI-46显著摄取而99mTc-奥曲肽扫描阴性:诊疗一体化应用的新希望
本文报告2例分化型甲状腺癌伴甲状腺球蛋白升高而碘闪烁显像阴性(TENIS综合征)患者,均行99mTc-奥曲肽扫描与99mTc-FAPI SPECT/CT评估转移灶。99mTc-奥曲肽扫描未见明显摄取,而99mTc-FAPI-46在转移灶呈强烈摄取;因诊断性扫描显示适当摄取,两例均被认为适合接受177Lu-FAPI-46治疗。
要点
- 2例TENIS综合征患者99mTc-奥曲肽扫描均未见明显摄取。
- 99mTc-FAPI-46 SPECT/CT显示转移灶强烈摄取。
- 因诊断扫描摄取适当,两例被认为适合177Lu-FAPI-46治疗。
核心结论
- 成纤维细胞激活蛋白抑制剂(FAPI)作为癌症诊断与治疗(诊疗一体化)的新型放射性药物,其作用仍在研究中。
- 2例TENIS综合征患者99mTc-奥曲肽扫描未见明显摄取,而99mTc-FAPI-46在转移灶显示强烈摄取。
- 因诊断性扫描显示适当摄取,这两例患者被认为适合接受177Lu-FAPI-46治疗。
研究设计与样本
- 本文报告2例分化型甲状腺癌伴甲状腺球蛋白升高而碘闪烁显像阴性(TENIS综合征)患者。
- 两例均行99mTc-奥曲肽扫描与99mTc-FAPI SPECT/CT以评估可能的转移部位。
主要发现
- 99mTc-奥曲肽扫描在这两例患者中均未见明显摄取。
- 99mTc-FAPI-46在转移灶呈强烈摄取:一例在肺、肝、肾上腺和腹部淋巴结可见恶性FAPI摄取,另一例在肺部可见。
- 因诊断性扫描显示适当摄取,这两例患者被认为适合接受177Lu-FAPI-46治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of fibroblast activation protein inhibitor (FAPI) as a novel radiopharmaceutical in the field of cancer diagnosis and treatment (theranostic) is still under investigation. We present 2 patients of differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome) who underwent 99mTc-OCTREOTIDE scan and 99mTc-FAPI SPECT/CT to evaluate possible sites for metastasis. 99mTc-OCTREOTIDE scan showed no remarkable uptake in these patients. On the other hand, foci of metastatic disease were found, with intense 99mTc-FAPI-46 uptake. Malignant FAPI uptake was evident in the lungs, liver, adrenal, and abdominal lymph nodes in a patient and in the lungs of another one. Due to proper uptake in diagnostic scans, these patients were recognized as a suitable candidate for treatment with 177Lu-FAPI-46.
引用
- Ghahraman M, Aryana K, Zakavi SR, et al. Significant 99mTc-FAPI-46 Uptake in 2 Cases of TENIS Syndrome With Negative Tc-OCTREOTIDE Scan, a New Hope in Theranostic Applications. Clin Nucl Med. 2025. PMID: 40179301. doi:10.1097/RLU.0000000000005817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。